Upadacitinib for itching and liver disease
Treatments studied
Part of Digestive system, Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests whether upadacitinib, a drug that calms the immune system, can help people with autoimmune liver disease and severe itching from atopic dermatitis (eczema). It aims to reduce itching and improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have moderate-to-severe itching from atopic dermatitis (eczema) that has lasted more than 6 months.
- You have primary biliary cholangitis or primary sclerosing cholangitis that has not improved with standard treatments.
- You have been on ursodeoxycholic acid (UDCA) for at least 3 months (for PSC) or 12 months (for PBC), plus other treatments.
- Your liver tests show elevated alkaline phosphatase (ALP) or gamma-glutamyl transferase (GGT).
- You do not have severe liver damage, other liver diseases, or certain infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
This trial tests an experimental drug called TH104 to see if it can reduce itching in people with primary biliary cholangitis. The study will help find out if TH104 is safe and effective for this symptom.
This study continues to test an experimental medicine (linerixibat) for itching caused by primary biliary cholangitis (PBC). It's for people who have already been in a prior study of this medicine and may help keep itching under control.
This trial tests an investigational medicine called linerixibat for people with primary biliary cholangitis (PBC) who have severe itching that hasn't responded to other treatments and who are at risk of serious complications from the itching. It aims to help reduce this itching and improve quality of life.
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
This trial tests a pill called upadacitinib to see if it can reduce painful mouth sores and scalp hair loss caused by lichen planus. It may help people who have not gotten better with topical steroid creams.
Hear when a new Primary Biliary Cholangitis (PBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.